Canton Strategic Holdings CNTN
NASDAQ CNTN
$2.28 +0.03 (+1.33%)
As of: Sep 4, 2026 · 3:59 PM EDT

Canton Strategic Holdings (CNTN) Cash from Financing Activities (2021 - 2026)

Canton Strategic Holdings' (CNTN) quarterly Cash from Financing Activities came in at $87.0 million in Q1 2026, up 42200.79% YoY from N/an in Q1 2025, and down 10.76% on a QoQ basis from $97.4 million in Q4 2025.

Analysis

Canton Strategic Holdings (CNTN) Cash from Financing Activities (2021 - 2026) Analysis & Trends

Canton Strategic Holdings (CNTN) has 6 years of Cash from Financing Activities data on file, last reported at $87.0 million in Q1 2026.

  • Quarterly Cash from Financing Activities rose 42200.79% year-over-year to $87.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193.9 million (up 5579.56% YoY) and the FY2025 annual result came in at $107.2 million, up 2939.54% from the prior year.
  • Cash from Financing Activities fell to $87.0 million in Q1 2026, from $97.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $97.4 million in Q4 2025 to a low of -$338585.0 in Q3 2022.
  • A 5-year average of $13.1 million and a median of $1.6 million in 2024 frame the typical range for Cash from Financing Activities.
  • Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 485.1% — and 2026, when it surged 42200.79%.
  • Tracing CNTN's Cash from Financing Activities over 5 years: stood at -$193457.0 in 2022, then surged by 5094.25% to $9.7 million in 2023, then slumped by 81.18% to $1.8 million in 2024, then soared by 5257.28% to $97.4 million in 2025, then decreased by 10.76% to $87.0 million in 2026.
  • The last three Cash from Financing Activities figures came in at $87.0 million (Q1 2026), $97.4 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Canton Strategic Holdings 493.37 Mn 493.37 Mn - 4.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.29 Mn
Mar 31, 2026 86.96 Mn
Dec 31, 2025 97.44 Mn
Sep 30, 2025 7.22 Mn
Jun 30, 2025 2.31 Mn
Mar 31, 2025 205,568.00
Dec 31, 2024 1.82 Mn
Sep 30, 2024 -257,730.00
Jun 30, 2024 1.65 Mn
Mar 31, 2024 317,119.00
Dec 31, 2023 9.66 Mn
Sep 30, 2023 -306,006.00
Jun 30, 2023 1.85 Mn
Mar 31, 2023 523,364.00
Dec 31, 2022 -193,457.00
Sep 30, 2022 -338,585.00
Jun 30, 2022 -249,643.00
Mar 31, 2022 13.85 Mn
Dec 31, 2021 -33,064.00
Sep 30, 2021 332,600.00